1. Inicio
  2. Publicaciones
  3. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience

Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience

Fecha de publicación: Fecha Ahead of Print:

Autores organización

Autores

  • Frias-Ordoñez, JS
  • Márquez, JR
  • Juliao-Baños, F
  • Galindo, P
  • Cuadros, C
  • Rojas, C
  • Rojas, N
  • Ardila, O
  • Tovar-Fierro, G
  • García-Duperly, R
  • Vargas, M
  • Flórez-Sarmiento, C

Grupos de investigación

Resumen

Introduction: There are no studies on efficacy of tofacitinib for ulcerative colitis (UC) in Latin America. The aim of this study was to describe the efficacy and safety, in the real world, of patients with moderate-severe UC treated with tofacitinib in our setting. Materials and methods: Multicenter descriptive observational study, in patients with UC who received treatment with tofacitinib in induction phase for 8 weeks and then, maintenance therapy, between June 2019 and June 2022. Results: Thirty-four adult patients, 50% female, mean age 38.1 (range 22-72) years. 76.5% pan colitis, and 20.6% left colitis. 79.4% failure to tumor necrosis factor inhibitors (anti-TNFs), and 35.3% to vedolizumab. 14.7% naive to biologic therapy. 23.5% had previous extraintestinal manifestations. During induction, 58.8% of patients achieved clinical, biochemical and endoscopic remission. During maintenance, 76.9% of patients at 26 weeks and 66.6% at 52 weeks presented clinical remission. Eight patients presented adverse events, none of them cardiovascular or thromboembolic. 44.1% were steroid-dependent, and 23.5% required steroids as rescue therapy. 38.3% required an increase in tofacitinib to 10 mg every 12 h during maintenance. In 17.6% tofacitinib was discontinued due to lack of efficacy. We included three pediatric-aged female patients, mean age 15.3 (range 14-17) years, 2/3 with pancolitis and 1/3 with left colitis, all with prior exposure to biologic therapy, who had clinical, biologic and endoscopic remission at induction. Conclusions: In this first Latin American study with tofacitinib in UC, efficacy and safety are demonstrated in the treatment of our patients with moderate to severe activity. (C) 2022 Elsevier Espana, S.L.U. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0210-5705,

Gastroenterologia Y Hepatologia  Ediciones Doyma, S.L.

Tipo:
Article
Páginas:
512-521

Citas Recibidas en Scopus: 5

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Ulcerative colitis; Janus kinase inhibitors; Tofacitinib; Inflammatory bowel diseases; Therapeutics; Disease management

Campos de estudio

Proyectos asociados

Análisis del viroma y el perfil de ácidos grasos de cadena corta intestinales en pacientes con espondilo-artritis y su relación con la actividad de la enfermedad

Investigador Principal: MARIA CONSUELO ROMERO SANCHEZ

PCI-2022-11053 . 2022

Desarrollo de un genosensor para la identificación de Helicobacter pylori en fluidos fisiológicos

Investigador Principal: SANDRA JANNETH PERDOMO LARA

PCI-2023-0020 . 2023

Citar la publicación

Compartir la publicación